UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide.

@article{Lago2002UCM707AP,
  title={UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide.},
  author={Eva de Lago and Javier Fern{\'a}ndez-Ruiz and Silvia Ortega-Guti{\'e}rrez and Alma Viso and Mar{\'i}a L. L{\'o}pez-Rodr{\'i}guez and Jos{\'e} Antonio Vera Ramos},
  journal={European journal of pharmacology},
  year={2002},
  volume={449 1-2},
  pages={99-103}
}
To date, UCM707, N-(3-furylmethyl)eicosa-5,8,11,14-tetraenamide, has the highest potency and selectivity in vitro as inhibitor of the endocannabinoid transporter, which might make this compound useful in potentiating endocannabinoid transmission, with minimal side-effects, in the treatment of several disorders. However, there is no information about how UCM707 behaves in vivo as regards certain classic effects of endocannabinoids, such as hypomotility and antinociception. In the present work… CONTINUE READING